Constellation Energy Climbs After Strong Q3 Results and Higher Full-Year Outlook
Company also announces Rhode Island acquisition plus Amazon, Google nuclear deals.
Already have an account? Sign in.
Company also announces Rhode Island acquisition plus Amazon, Google nuclear deals.
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
The acquisition adds Frontage’s clinical bioanalysis expertise and strengthens Charles River’s drug development offering.
Be the first to know when deals break, stocks move, or biotech headlines hit.